Sacred Journey Recovery in Vista, CA Offers a Life-Changing Approach to Men's Addiction Treatment Amid Rising Meth and Fentanyl Use
The program's foundation is built on an integrated clinical model that utilizes evidence-based therapies including Dialectical Behavioral Therapy, Cognitive Behavioral Therapy, Acceptance and Commitment Therapy, and Narrative Therapy. These modalities go beyond surface-level coping strategies and reach into the core of what fuels addiction. DBT helps men gain control over impulsive behaviors and intense emotional swings. CBT rewires distorted beliefs and habits that perpetuate substance use. ACT teaches clients how to move through pain while still acting in alignment with their personal values, and Narrative Therapy gives men the chance to redefine their identity through a more empowered lens. These methods are not simply confined to the therapy room. They are actively lived out—on hiking trails, climbing walls, and in deep fireside conversations that foster trust and growth.
What truly elevates the experience at Sacred Journey Recovery is its use of cutting-edge brain mapping technology, or QEEG. This non-invasive diagnostic tool captures a snapshot of the brain's electrical activity, offering insights into overactive or under-functioning regions that may be contributing to anxiety, depression, trauma, or cognitive difficulties. By understanding the brain's patterns, clinicians can create highly customized treatment plans while giving clients a visual representation of how their brain is healing throughout the recovery journey. It also serves a larger purpose: reframing addiction as a brain-based disorder rather than a moral failure, which can be a transformative shift for men who have carried deep shame into treatment.
The treatment model extends beyond clinical interventions. Sacred Journey Recovery's program is rooted in mentorship, community, and challenge. Clients participate in experiential therapies that include hiking, camping, indoor skydiving, wolf therapy, and structured rites of passage. These experiences are not recreational extras—they are designed to facilitate breakthroughs, cultivate resilience, and foster a sense of earned confidence and brotherhood. In a world where men are often isolated and discouraged from emotional expression, Sacred Journey creates space for connection, self-reflection, and leadership.
San Diego County's rising overdose rates, particularly from fentanyl-laced street drugs and methamphetamine, have placed an urgent spotlight on the need for accessible, innovative care. Vista, located in the heart of North County, has become a critical area of focus. Sacred Journey's outpatient model includes both Partial Hospitalization Programs (PHP) and Intensive Outpatient Programs (IOP), providing structured, consistent care while allowing clients to gradually reenter work, family, and community life. The facility also partners with trusted sober living homes, giving clients the stability and support they need during this transitional period.
One family member who witnessed the transformation firsthand shared, 'Sacred Journey Recovery is an incredible men's rehab in sunny Vista, CA offering adventure-based PHP and IOP programs. Their team combines clinical care with real-world healing through outdoor wilderness therapy, wolf therapy, brotherhood, and holistic support. Taking their clients hiking, rappelling, camping, indoor skydiving really sets them apart in the recovery space. Their sober living partnerships help clients succeed beyond treatment. Highly recommend for any man who is ready to transform their life.'
At a time when men across California are facing overwhelming pressure from addiction, trauma, and disconnection, Sacred Journey Recovery is offering something bold and vital: a place to rediscover strength, reclaim purpose, and build a life worth staying sober for. With clinical integrity, deep brotherhood, and adventure at its core, this Vista-based center is not only changing lives—it's redefining what recovery can be.
###
For more information about Sacred Journey Recovery, contact the company here:
Sacred Journey RecoveryDrew Anagnostou760-888-5202
[email protected]
161 Thunder Drive #214, Vista, California 92083
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Gynecological Devices Market Valuation to Reach US$ 20.19 Billion By 2033
Driven by an aging population and a strong shift toward minimally invasive procedures, the market is dominated by surgical devices and robotics. Hospitals and clinics remain primary end-users, investing heavily in advanced technology despite reimbursement pressures. Chicago, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The global gynecological devices market was valued at US$ 10.18 billion in 2024 and is expected to reach US$ 20.19 billion by 2033, growing at a CAGR of 7.90% during the forecast period 2025–2033. The global gynecological devices market is currently navigating a period of profound and accelerated transformation. This is not a gradual evolution but a dynamic surge, creating a landscape rich with opportunity for manufacturers, investors, and healthcare systems worldwide. A confluence of powerful drivers—including an unprecedented influx of venture capital into women's health technology, the escalating prevalence of complex gynecological conditions, and a wave of disruptive technological advancements—is fueling this robust growth. The market is moving beyond incremental improvements toward fundamental shifts in diagnostics and therapeutics. Free Report Sample Available for Immediate Download: An exhaustive analysis of data reveals a compelling, multi-layered narrative of expansion. This in-depth market research report dissects nine critical segments, presenting meticulously researched, data-driven insights that collectively illuminate the immense and multifaceted opportunities materializing across the global gynecological devices market. Key Finding in Gynecological Devices Market Market Forecast (2033) US$ 20.19 billion CAGR 7.90% Largest Region (2024) North America (42%) By Product Surgical Devices (53.0%) By End Users Hospitals & Clinics (65.26%) Top Drivers Rapidly aging female population creates a growing patient base. Government initiatives are increasingly focused on promoting women's health. High adoption of advanced and innovative medical technologies. Top Trends Rising physician preference for minimally invasive surgical techniques. Growing use of robotic-assisted surgery for gynecological procedures. Increased focus on early diagnostics with advanced imaging systems. Top Challenges Strict and lengthy regulatory approval cycles for new devices. Declining national birth rate impacting obstetrics device demand. Stringent reimbursement policies and pressure on healthcare cost containment. Venture Capital Investment Ignites a Firestorm of Femtech and Gynecological Device Innovation The financial landscape for women's health has been transformed by a massive surge of venture capital, directly spurring innovation and growth in the gynecological devices market. Funding for femtech startups has exceeded US$5 billion since 2020, with US$1.2 billion deployed in 2024 alone. Broadening the view to all women's health startups brings the 2024 total to US$2.6 billion, and, including all women-centric conditions, investment in the US and Europe reached nearly US$10.6 billion in 2024. This is a truly global trend. In Europe, €339.4 million was invested across 47 femtech deals in 2024, and European femtechs had already attracted over €334 million in venture capital by March 2025. This capital empowers companies to launch breakthrough products, fueling a new wave of innovation. Recent examples include Future Family securing a US$400 million financing program in April 2025 and ByHeart raising US$72 million the same month for manufacturing expansion. Significant 2025 investments underscore the diversity of innovation: Gesynta Pharma (US$29 million) and Conceivable Life Sciences (US$18 million) are advancing novel treatments, while Delfina (US$17 million), Twentyeight Health (US$10 million), and Teal Health (US$10 million) highlight the growing impact of AI-powered maternal health and accessible care. The funding cascade continues with Kegg (US$6.5 million), Egal (US$4 million), Fizimed (€4 million), Ema (US$3 million), Trellis Health (US$1.8 million), Raaz (US$1 million), Calla Lily (£1 million), Mabel (€600,000), Femble (€350,000), and AuraFem Health (US$200,000). The UNICEF Venture Fund further nurtures innovation, offering up to US$100,000 in equity-free funding for emerging economies, ensuring support at every level. Addressing Uterine Fibroids Creates a Significant and Highly Costly Market Opportunity Uterine fibroids represent a highly prevalent and economically significant condition, creating a vast and sustained demand for effective therapeutic solutions within the gynecological devices market. The sheer scale of this public health issue is immense. As of 2024, the estimated annual economic cost of uterine fibroids in the United States has escalated to an astonishing US$41.4 billion. A major component of this economic burden is productivity loss, with an estimated US$17.2 billion lost annually in the U.S. due to missed work and short-term disability. The patient population itself is expanding, with data showing that the number of women in the U.S. diagnosed with uterine fibroids increased by 10.6% between 2010 and 2022. This steady growth signals a consistently expanding patient base requiring treatment. The high out-of-pocket cost of traditional surgical interventions further amplifies the market need for innovative, less invasive, and more cost-effective devices. Without insurance coverage, a myomectomy procedure can cost between US$11,000 and US$22,000, while a full hysterectomy ranges from US$9,600 to US$24,000. Alternative, device-centric treatments also carry substantial price tags, with uterine artery embolization costing between US$10,000 and US$15,000, and radiofrequency ablation ranging from US$8,900 to US$20,000. These costs exhibit significant geographic variability; for instance, a laparoscopic hysterectomy could cost approximately US$28,000 in Cleveland, Ohio, while the same procedure in Atlanta, Georgia, might be closer to US$19,000. This cost-prohibitive environment creates a powerful incentive for the adoption of new technologies in the gynecological devices market that can offer superior outcomes at a lower total cost of care. Assisted Reproductive Technology Forges a Burgeoning and Profitable Niche Device Market The increasing societal demand for fertility assistance, driven by trends such as delayed parenthood and rising infertility rates, is a potent force shaping a specialized and highly profitable segment of the gynecological devices market. The global demand for these services is immense, with approximately 2.5 million In-Vitro Fertilization (IVF) cycles now being performed annually across the world. This trend is particularly pronounced in the United States, where the number of IVF cycles performed in SART (Society for Assisted Reproductive Technology) member clinics surged from 389,993 in 2022 to 432,641 in 2023. These procedures directly resulted in the birth of 95,860 babies in the U.S. in 2023. Comprehensive data from 2021 shows that 238,126 patients in the U.S. initiated a total of 413,776 ART cycles, demonstrating the high volume of procedures. The financial investment from patients is substantial and directly fuels demand for the sophisticated equipment, consumables, and diagnostic tools used in these delicate procedures. The average cost of a single IVF cycle in the U.S. ranges from US$12,000 to US$17,000, with some reports from the Department of Health and Human Services placing the potential cost between US$15,000 and US$20,000. This sustained, high-value patient expenditure ensures a robust and growing revenue stream for manufacturers of the specialized instruments essential to modern fertility treatment, making it a cornerstone of the modern gynecological devices market. Robotic Surgery Revolutionizes Gynecological Procedures and Propels Advanced System Device Adoption Minimally invasive robotic surgery has become the gold standard for many gynecological procedures, offering greater precision, shorter recovery times, and improved patient outcomes. This shift is driving rapid adoption of advanced robotic surgical systems, with the da Vinci system leading the market. In 2024 alone, 2,683,000 procedures were performed globally using da Vinci systems, reflecting exponential usage growth. Hardware sales surged as well, with 493 da Vinci surgical systems placed in healthcare facilities in Q4 2024, bringing full-year placements to 1,526. This expansion resulted in substantial financial gains: Intuitive Surgical reported US$2.41 billion in revenue for Q4 2024, up 25% from the previous year. Recurring revenue in the gynecological devices market from proprietary instruments and accessories climbed to US$1.41 billion in Q4, while capital sales of the systems hit US$1.97 billion for the full year. The da Vinci system generally sells for US$0.7 million to US$3.1 million, signifying significant capital commitment from hospitals. By 2020, over 5,500 da Vinci systems were installed in U.S. hospitals, with more than 2,000 hospitals nationwide now utilizing robotic surgery systems. This robust infrastructure supports continued growth: the global gynecological surgery robot market reached approximately US$3.2 billion in 2024 and is poised for further expansion. The outlook is especially strong given that nearly 600,000 hysterectomies are performed in the U.S. every year, many ideal for robotic assistance. Rising Prevalence of Pelvic and Endometrial Disorders Spurs Urgent Device Innovation A growing awareness among both patients and clinicians regarding the diagnosis and treatment of widespread yet historically underdiagnosed conditions such as endometriosis and pelvic organ prolapse (POP) is opening new frontiers for the gynecological devices market. The addressable patient population is substantial and expanding. Projections indicate that the number of American women suffering from at least one pelvic floor disorder is set to increase to 43.8 million by the year 2050. More specifically, the number of women with POP in the U.S. is expected to climb to 4.9 million by 2050, while the global population of POP patients is projected to reach an enormous 156 million by 2036. For endometriosis, a condition infamous for its diagnostic challenges, the average time from symptom onset to a definitive diagnosis is currently a staggering 8 years and 10 months. This diagnostic delay represents a critical unmet need and a clear opportunity for innovative diagnostic devices. Promising clinical research is underway to address these therapeutic gaps. A clinical trial involving 36 participants is evaluating a cannabidiol extract for endometriosis pain and is expected to conclude in December 2024, while another larger pain reduction trial with 102 participants is set to conclude in August 2024. Success in these trials could pave the way for new treatment paradigms supported by new devices. At-Home Testing Empowers Consumers and Rapidly Expands the Diagnostic Device Market A fundamental paradigm shift toward patient-centric care, emphasizing convenience, privacy, and empowerment, is fueling explosive growth in the at-home testing sector. This consumer-driven movement represents a critical expansion corridor for the diagnostic segment of the gynecological devices market. The market size reflects this rapid adoption; the global at-home testing market is estimated to reach a value of US$7,789.1 million in 2025, a healthy increase from its US$7,432.3 million valuation in 2024. The fertility testing sub-market is a particularly strong contributor to this growth, and it is estimated to be valued at US$672.9 million in 2025. Long-term projections are even more bullish, with the global Ovulation Test Market projected to expand to US$4.04 billion by 2032. Similarly, the broader global Fertility Testing Devices Market, which was valued at US$702.59 million in 2023, is projected to surge to an impressive US$1,171.55 million by 2032. The distribution channels for these devices are also modernizing to meet consumer demand. The online pharmacy segment has emerged as the dominant channel, holding the largest share of the fertility testing devices market in 2023 at 41.12%. This trend opens up a powerful direct-to-consumer channel, reshaping marketing and logistics for the entire gynecological devices market. Core Surgical and Diagnostic Device Advancements Enhance Overall Patient Care Efficacy Relentless and continuous innovation in the design and function of core surgical and diagnostic instruments remains a fundamental pillar of growth for the gynecological devices market. These advancements directly translate into improved clinical efficacy, enhanced safety profiles, and better patient experiences. A landmark development occurred in 2025 when Kephera Diagnostics launched its EndomTest, which stands as the first commercially available non-invasive blood test for endometriosis in the United States. This represents a significant leap forward in diagnostics. Simultaneously, the regulatory environment is adapting to support and safeguard this innovation. In November 2024, the Food and Drug Administration (FDA) announced a new communications pilot program specifically designed to enhance the medical device recall process, a program that explicitly includes obstetrics and gynecology devices. This heightened focus on safety is critical, as evidenced by an April 2024 recall of Boston Scientific's Obsidio Embolic device. A comprehensive review of high-risk recalls from 2002 through 2016 identified 7 distinct class I recall events that affected over 88,000 women's health medical devices. This history informs the current proactive regulatory stance, which ultimately fosters greater trust and ensures the long-term, sustainable health of the gynecological devices market. Tailor This Report to Your Specific Business Needs: The Staggering Economic Burden of Gynecological Conditions Underscores Urgent Device Need The immense economic weight imposed by common gynecological conditions on healthcare systems, employers, and patients provides a powerful and persuasive argument for the value proposition of effective and cost-efficient medical devices. The annual economic burden of uterine fibroids in the U.S. is a clear example, estimated to be as high as US$41.4 billion. A major driver of this staggering cost is the impact on workforce productivity, with lost wages due to fibroids costing American women approximately US$17.2 billion every year. The economic drain extends beyond fibroids. The annual surgical costs in the U.S. for treating pelvic organ prolapse now exceed US$1.523 billion. These multi-billion-dollar figures create a compelling business case for payers and healthcare providers to aggressively invest in advanced gynecological devices. Devices that can reduce the need for expensive surgeries, shorten hospital stays, minimize recovery times, and mitigate long-term complications offer a clear and quantifiable return on investment. This powerful economic reality serves as a persistent and significant demand driver for the entire gynecological devices market. Global Gynecological Devices Market Major Players: Karl Storz SE & Co. KG Hologic Inc. Boston Scientific Corporation B. Braun Melsungen AG Becton, Dickinson and Company CONMED Corporation CooperSurgical Inc. Coloplast A/S Johnson & Johnson (Ethicon) Medtronic plc Olympus Corporation Stryker Corporation Richard Wolf GmbH Intuitive Surgical Teleflex Incorporated Minerva Surgical Inc. Lumenis Ltd. Other Prominent Players Market Segmentation: By Product Surgical Devices Gynecological Imaging Devices Portable Tools By End Use Hospital & Clinics Ambulatory Surgery Centers (ASCs) By Region North America Europe Asia Pacific Middle East Africa South America Explore the Report Before You Buy – Book a Walkthrough: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
Yahoo
7 hours ago
- Yahoo
Pharmacovigilance Automation Market Size, Key Players and Trends 2025
The pharmacovigilance automation market is gaining strong momentum worldwide, with projections indicating it will generate hundreds of millions in revenue between 2025 and 2034. Ottawa, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The pharmacovigilance automation market size growth is being driven by rising investments, ongoing innovation, and increasing demand across the healthcare and pharmaceutical sectors, a study published by Towards Healthcare a sister firm of Precedence Research. Get a free sample to explore key trends, market drivers, and growth insights: A key reason for this expansion is the tightening of global drug safety regulations and the need to better manage the growing number of adverse drug reactions. To meet these challenges, companies are turning to advanced technologies like artificial intelligence, natural language processing (NLP), and machine learning. These tools are helping automate tasks such as collecting, identifying, and analyzing adverse events making the process faster, more accurate, and cost-effective. Regionally, North America is leading the market thanks to heavy R&D spending by pharma companies and a strong digital healthcare infrastructure. Meanwhile, Asia Pacific is emerging as the fastest-growing region, driven by a high volume of clinical trials and a robust regulatory landscape. Key Takeaways North America is dominant in the pharmacovigilance automation market in 2024 with a 45% share. Asia Pacific is estimated to grow at the fastest CAGR from 2025 to 2035. By function, the case processing & reporting segment for the largest market revenue in 2024, with a 42% share. By function, the regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. By technology, the robotic process automation (RPA) segment is dominant in the market in 2024 with a 36% share. By technology, the natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. By deployment mode, the cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. By end user, the pharmaceutical & biotechnology companies segment is dominant in the market in 2024 with a 48% share. By end user, the academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Market Overview & Potential What is the Growth Potential Responsible for the Growth of the Pharmacovigilance Automation Market? The growth of the market is driven by the growing demand and increasing drug development, fueled by the expanding pharmaceutical industry's demand for safety monitoring systems, which in turn fuels the growth of the market. The rising adverse drug reactions monitoring due to increasing chronic diseases demands effective pharmacovigilance practices. Other key growth drivers are the regulatory stringency, technological advancement to automate the task and improve the accuracy, and to streamline the assessment boosts the growth and expansion of the market. What are the Growing Trends Associated with the Pharmacovigilance Automation Market? AI and Machine Learning: AI and ML are increasingly utilized to automate various tasks such as identifying adverse events, extracting data from unstructured sources like social media, and monitoring literature. Automated Case Processing: Organizations are swiftly implementing automation for case handling, including intake, triage, and analysis, resulting in quicker reporting and greater efficiency. Big Data Analytics: Pharmacovigilance is employing big data analytics to detect patterns and correlations within large datasets, supporting signal detection and risk management. Real-World Evidence (RWE): The use of real-world data information collected outside clinical trials is on the rise, with automation playing a vital role in managing and analyzing this data effectively. Remote Work and Collaboration: The pandemic has sped up remote work adoption, and automation tools are facilitating improved collaboration and communication among pharmacovigilance teams. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growing Challenge in the Pharmacovigilance Automation Market? The key challenge that limits the growth of the Asia Pacific bioplastics market is the lack of sufficient funding for pharmacovigilance activities, resulting in limited implementation of advanced automation solutions, which limits the growth of the market. Other key challenge the is the shortage of skilled professionals who are experts in pharmacovigilance and automation technologies, which is a challenge and hinders the growth and expansion of the market. Regional Analysis How did North America Dominate the Pharmacovigilance Automation Market in 2024? North America dominated the pharmacovigilance automation market share by 45% in 2024, with a 45% share, driven by early adoption of automation in healthcare, including PV, which effectively manages inventory, orders, and tracking, ensuring proper medicine delivery and reducing errors. The FDA's Adverse Event Reporting System (FAERS) supports market growth by tracking adverse drug reactions and medication errors. Advanced technology infrastructure, stringent FDA regulations, and growing AI adoption promote pharmacovigilance automation. Emphasis on real-time data analytics, electronic health records integration, and robust drug safety frameworks drives automated adverse event reporting and signal detection to enhance patient safety and regulatory compliance. Canada's focus on digital health transformation, Health Canada's regulatory support, and investment in AI-powered pharmacovigilance tools promote automation. Collaboration among healthcare providers, researchers, and tech companies accelerates real-world data utilization, improving adverse event monitoring and drug safety through streamlined, automated reporting systems. What Made Asia Pacific Significantly Grow in the Pharmacovigilance Automation Market in 2024? The Asia Pacific region is projected to experience the fastest growth during the forecast period. Its rise is fueled by rapid product launches in healthcare, increasing consumer expectations, and the expanding use of digital health technology. Ongoing healthcare transformation, supported by policies, infrastructure development, and public-private partnerships, positions APAC to become a global leader in digital health, thus propelling market growth of market growth. China's expanding pharmaceutical industry, government initiatives for digital health, and adoption of big data and AI technologies drive pharmacovigilance automation. The National Medical Products Administration encourages automation to enhance drug safety surveillance, leveraging vast healthcare data to improve adverse event detection and regulatory oversight. India's growing pharmaceutical sector, government policies supporting digital health, and increased AI integration promote pharmacovigilance automation. The Central Drugs Standard Control Organization encourages automated adverse event reporting to enhance patient safety. Collaborative efforts between government, industry, and academia drive the adoption of technology for efficient drug safety monitoring. Get the latest insights on life science industry segmentation with our Annual Membership: Segmental Insights By function The case processing & reporting segment for the largest pharmacovigilance automation market revenue in 2024, with a 42% share. It provides data for investigating adverse effects, enabling the identification of new safety concerns and occasional assessment of the profit-to-challenge ratio for pharmaceutical use. It facilitates data exchange among stakeholders like patients, healthcare professionals, and authorities by sharing large volumes of safety information. Case reports play a key role in detecting new safety signals through the description of rare or delayed adverse effects that might not be observed in clinical trials. The regulatory compliance automation segment is estimated to fastest-growing over the forecast period, 2025 to 2035. Automation in regulatory compliance ensures that medications and healthcare devices meet strict standards of quality, safety, and efficacy before market release. Agencies such as the FDA, EMA, and WHO enforce guidelines like GMP, GCP, and GDP throughout all stages of development and distribution. Following these guidelines is crucial for maintaining public trust and ensuring success in the medical industry. By technology The robotic process automation (RPA) segment is dominant in the pharmacovigilance automation market in 2024 with a 36% share. Robotic process automation (RPA) enhances operational efficiency by streamlining workflows, reducing risks, and minimizing delays and rework, which lowers operational costs. RPA offers privacy and security benefits, helps pharmaceutical companies reduce human errors, and improves data accuracy to support better decision-making. In pharmacovigilance, RPA is especially valuable for faster adverse effect response times. The natural language processing (NLP) segment is expected to register the fastest growth over the forecast period, 2025 to 2035. NLP has become essential in pharmacovigilance, a field focused on monitoring and preventing drug-related adverse effects. It efficiently manages vast amounts of unstructured data such as patient records and social media posts, which provide real-world insights into drug effects. NLP aids in regulatory compliance and accelerates reporting to health authorities. By deployment mode The cloud-based segment is dominant in the pharmacovigilance automation market in 2024, and it is expected to sustain the position during the forecast period with a 61% share. Cloud solutions deliver robust security features like data encryption, secure access protocols, and regular backups. As an emerging tool, cloud-based systems in pharmacovigilance support seamless data integration by providing internet-based storage, computing services, analytics, and software, thus enhancing efficiency. By end user, The pharmaceutical & biotechnology companies segment is dominant in the pharmacovigilance automation market in 2024 with a 48% share. Pharmacovigilance companies share core goals with government agencies: protecting patients from harm by detecting hidden drug complexities early, identifying risk factors, debunking false safety signals, and addressing benefit challenges. PV raises awareness among healthcare professionals and patients regarding contraindications, indications, doses, administration routes, and adverse effects. The academic & research institutions segment is expected to register the fastest growth over the forecast period, 2025 to 2035. Pharmacovigilance also hosts leading research platforms that improve patient care through informed prescribing and ensure government compliance. These collaborations with top industry players further fuel market growth. Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: Recent Developments in the Pharmacovigilance Automation Market In July 2025, Tata Consultancy Services (TCS) was recognized as a Leader in Everest Group's PEAK Matrix for Pharmacovigilance (PV) Operations services. The report emphasizes TCS's extensive pharmacovigilance offerings, including device complaint management, medical device product quality issues, medical device reporting, and post-market surveillance as key strengths. TCS's flagship ADD safety platform is notably highlighted for its touchless processing of individual case safety reports (ICSRs), featuring integrated quality control, smart signal detection, literature surveillance, and safety report generation. In September 2024, Truliant Consulting releases a white paper titled AI and Automation in Pharmacovigilance: Transformative Trends and Future Outlook. This paper results from an open survey aimed at pharmaceutical companies to explore their adoption of artificial intelligence (AI) within their Pharmacovigilance (PV) frameworks. Top Companies and Their Contributions to the Market Company Contributions & Offerings Oracle Corporation Provides cloud-based safety and pharmacovigilance solutions, integrating AI for automated case processing and compliance management. Veeva Systems Inc. Offers cloud software tailored for life sciences, including pharmacovigilance modules that streamline safety data management and reporting. ArisGlobal Develops end-to-end drug safety and pharmacovigilance platforms with automation, AI, and regulatory compliance features. IQVIA Combines real-world data analytics with automation to enhance signal detection, adverse event reporting, and clinical safety workflows. Cognizant Technology Solutions Delivers IT and BPO services focusing on automated pharmacovigilance processes, leveraging AI and machine learning for data accuracy. Accenture Provides digital transformation and AI-driven pharmacovigilance automation services to optimize safety data workflows globally. Genpact Specializes in AI-powered pharmacovigilance automation, improving adverse event case processing and regulatory reporting efficiency. Tata Consultancy Services (TCS) Offers integrated technology solutions automating safety data capture, analysis, and regulatory submissions in pharmacovigilance. Parexel International Corporation Provides clinical research and safety automation services, enhancing pharmacovigilance with AI-enabled case management and reporting tools. ICON plc Focuses on clinical research and drug safety automation, utilizing advanced analytics and automated adverse event monitoring systems. Pharmacovigilance Automation Market Key Players List Oracle Corporation Veeva Systems Inc. ArisGlobal IQVIA Cognizant Technology Solutions Accenture Genpact Tata Consultancy Services (TCS) Parexel International Corporation ICON plc Capgemini SE PharmaLex GmbH Indegene Pvt Ltd BioClinica (part of ERT) Infosys Limited HCL Technologies Ennov Tech Mahindra Zifo RnD Solutions NNIT A/S Browse More Insights of Towards Healthcare: Global Pharmaceutical & Compounding Market Outlook (2024–2034) The pharmaceutical and healthcare packaging sectors are undergoing notable transformation, supported by rising demand for personalized treatments, automation, and regulatory compliance. Here's a breakdown of key market trajectories: GCC Compounding Pharmacy MarketThe GCC compounding pharmacy market is witnessing a strong upward trend. Valued at USD 16.39 million in 2024, it is expected to reach approximately USD 40.26 million by 2034, growing at a CAGR of 9.27%. This growth is driven by the increasing need for tailored medications across the Gulf region. Global Non-Sterile Compounding Pharmacy MarketThe non-sterile compounding pharmacy market was estimated at USD 5.97 billion in 2024 and is set to almost double by 2034, reaching around USD 12.11 billion. With a CAGR of 7.34%, the market reflects expanding demand for dosage flexibility and patient-specific drug formulations. Global Pharmacy Automation MarketThe pharmacy automation market is advancing rapidly as healthcare systems adopt technologies to streamline dispensing and improve safety. Starting at USD 6.35 billion in 2024, the market is projected to reach USD 16.65 billion by 2034, growing at a CAGR of 10.12%. Global Compounding Pharmacy MarketThe global compounding pharmacy market stood at USD 13.19 billion in 2023 and is projected to climb to USD 22.91 billion by 2034. This steady growth, at a CAGR of 5.15%, is propelled by rising chronic disease prevalence and the need for customized drug therapies. Global Vials Used in Compounding Pharmacy MarketThe vials used in compounding pharmacy market is set for strong revenue growth over the forecast period. The market is expanding in response to higher demand for safe and precise medication containers, especially in sterile compounding. Global Biotechnology & Pharmaceutical Services MarketThe biotechnology and pharmaceutical services market is projected to grow from USD 76.51 billion in 2024 to around USD 130.56 billion by 2034, at a CAGR of 5.48%. The market benefits from increased outsourcing, R&D intensity, and regulatory support. Global Biopharmaceuticals CRO MarketThe biopharmaceuticals CRO (Contract Research Organization) market is on a robust growth path. With rising R&D and a push for cost efficiency, the market is expected to generate significant revenue gains through 2034. Global Pharmaceutical Spray Drying MarketThe pharmaceutical spray drying market is valued at USD 2.37 billion in 2024 and forecast to nearly double, reaching USD 4.93 billion by 2034. A CAGR of 7.67% reflects the increased use of this technology for enhancing bioavailability in drug formulations. Global Ready-to-Use Pharmaceutical Packaging MarketThe ready-to-use pharmaceutical packaging market was valued at USD 10.4 billion in 2024 and is anticipated to reach USD 20.97 billion by 2034. Growing at a CAGR of 7.24%, this market is shaped by demand for efficiency, sterility, and compliance. Global Pharmaceutical Secondary Packaging MarketThe pharmaceutical secondary packaging market is estimated at USD 43.11 billion in 2024 and is expected to grow to USD 69.45 billion by 2034. With a CAGR of 4.94%, this segment is critical for safety labeling, tracking, and brand protection. Segments Covered in The Report By Function Case Processing & Reporting Case Intake Medical Review Data Entry & Coding Signal Detection & Management Literature Screening Regulatory Compliance Automation Risk Management & Benefit-Risk Evaluation Report Submission & Distribution Quality Control & Reconciliation By Technology Robotic Process Automation (RPA) Artificial Intelligence (AI) & Machine Learning Natural Language Processing (NLP) Cloud-Based PV Platforms Rules-Based Automation Tools Intelligent Automation By Deployment Mode On-Premises Cloud-Based By End User Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) Pharmacovigilance Service Providers Regulatory Agencies Academic & Research Institutions By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait To invest in our premium strategic solution and customized market report options, click here: You can place an order or ask any questions, please feel free to contact us at sales@ Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
8 hours ago
- Business Upturn
D-dimer Testing Market Size to Hit USD 2.74 Billion by 2032, Fueled by Rising Incidence of Thrombotic Disorders and Aging Population
Austin, Aug. 05, 2025 (GLOBE NEWSWIRE) — D-dimer Testing Market Size & Growth Analysis: According to SNS Insider, The D-dimer Testing Market was valued at USD 1.83 billion in 2023 and is projected to reach USD 2.74 billion by 2032, growing at a CAGR of 4.59% during the forecast period 2024–2032. The U.S. D-dimer Testing Market alone contributed USD 0.43 billion in 2023 and is projected to reach USD 0.59 billion by 2032, showcasing consistent demand in a region with a high prevalence of thrombotic and cardiovascular diseases. Get Free Sample Report of the D-dimer Testing Market: D-dimer testing is increasingly being adopted for its critical role in diagnosing deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). The rise in chronic conditions, aging global populations, and post-COVID-19 complications are expected to further fuel demand. Key Growth Drivers: Rising Prevalence of Thrombotic Events: Sedentary lifestyles, obesity, and smoking contribute to growing cases of DVT and PE. Aging Population: Older adults are more susceptible to clotting disorders, increasing demand for rapid diagnostic solutions. Point-of-Care Testing (POCT) Advances: Technological innovations are expanding test accessibility across outpatient and emergency care settings. Healthcare Infrastructure Expansion in Emerging Markets: Developing regions are investing in diagnostic technologies to improve patient outcomes. Major Players Analysis Listed in this Report are: Siemens Healthcare Biomedica Diagnostics Abbott Thermo Fisher Scientific Inc. WERFEN HORIBA, Ltd. SEKISUI Diagnostics F. Hoffmann-La Roche Ltd BIOMÉRIEUX QuidelOrtho Corporation Diazyme Laboratories Segment Analysis By Product: The market is led by the reagents & consumables segment in 2023, which held a share of 61.1% owing to its high-volume use for repetitive testing as well as rising demand for standardized product kits available at hospitals and laboratories. Test operation essential: Dynamic filling and dumping, consumables must be recycled frequently. By Test Type: Clinical laboratory tests held the majority share of 59.5% in 2023 on account of higher throughput and the fact that they can process bulk testing effectively, especially in hospitals & diagnostic centers. However, point-of-care tests (POCT) are experiencing the fastest growth owing to their rising application in the emergency department and outpatient care. A major driver is their potential to deliver fast, actionable results at the bedside or in ambulances. By Method: In 2023, the ELISA was responsible for a 39.6% market share driven by its proven efficiency and scalability to clinical lab settings with high accuracy levels. The latex-enhanced immunoturbidimetric assay is a rapidly expanding method with a shorter turnaround time and full integration into automated analyzers, which allows rapid high-throughput testing. By Application: The highest DVT market share was for the deep vein thrombosis (DVT) segment in 2023, with a global spread and significant clinical emphasis on its early detection. Pulmonary embolism (PE) is turning out to be the fastest growing segment, and this growth is particularly attributed to an increase in awareness as well as advancements in detection technologies across emergency medicine. By End-Use: Hospitals controlled the largest share of the market in 2023, at 32.8%. This occurs because of the large number of emergency, ICU, and in-house laboratories capable of carrying out rapid diagnostic work-ups. For a Personalized Briefing with Our Industry Analysts, Connect Now: D-dimer Testing Market Segmentation By Product Analyzers Reagents & Consumables By Test Type Clinical Laboratory Tests Point-of-Care Tests By Method Enzyme-linked Immunosorbent Assay (ELISA) Latex-enhanced Immunoturbidimetric Assays Fluorescence Immunoassays Others By Application Deep Vein Thrombosis (DVT) Pulmonary Embolism (PE) Disseminated Intravascular Coagulation (DIC) Others By End-Use Hospitals Academic & Research Institutes Diagnostic Centers Others Regional Analysis The market in North America is expected to grow at the highest CAGR during the forecast period, driven by high healthcare expenditure, strong laboratory testing base, and a well-developed physician network. The U.S., especially, has high diagnostic rates and cardiovascular disease incidence, thus ruling the region. Asia Pacific is the largest growing region for the anticipated period. The diagnostic field is experiencing an exponential growth in several countries, such as China and India, driven by escalating investments toward healthcare infrastructure development and growing accessibility to POCT products. Several drivers contribute to RT acceptance: heightened public awareness, wider insurance coverage, and government moves against noncommunicable disease. Recent Advances in D-dimer Testing Market Feb 2023 – Carolina Liquid Chemistries Corp. and Diazyme Laboratories added D-dimer to its test menu on the DZ-Lite c270 analyzer, part of a batch of 25 new assays to give diagnosticians more flexibility. April 2024 – Siemens Healthineers introduced an enhanced D-dimer assay to the Atellica Solution platform, which provided enhanced sensitivity and turnaround times for emergency settings. Suggested Unique USP Sections for Client Proposal Prevalence-Based Demand Modeling – Country-wise mapping of thrombotic disease burden vs. current D-dimer testing rates. – Country-wise mapping of thrombotic disease burden vs. current D-dimer testing rates. Point-of-Care Ecosystem Analysis – Mapping adoption trends and infrastructure requirements for POCT expansion across regions. – Mapping adoption trends and infrastructure requirements for POCT expansion across regions. Regulatory & Reimbursement Landscape – Coverage policies, regional regulatory hurdles, and HTA frameworks impacting test adoption. – Coverage policies, regional regulatory hurdles, and HTA frameworks impacting test adoption. AI Integration & Diagnostic Decision Support – Innovations around AI-enhanced interpretation of D-dimer results for clinical triage. – Innovations around AI-enhanced interpretation of D-dimer results for clinical triage. Hospital-Laboratory Partnership Models – Case studies on how labs and hospitals are optimizing diagnostic turnaround and cost via partnerships. – Case studies on how labs and hospitals are optimizing diagnostic turnaround and cost via partnerships. Workflow & Automation Impact Analysis – Efficiency benchmarking of automated platforms vs. manual processing for D-dimer testing. – Efficiency benchmarking of automated platforms vs. manual processing for D-dimer testing. D-dimer in Multi-Analyte Panels – Future scope and pipeline analysis of D-dimer integration into cardiovascular or coagulation biomarker panels. Buy the Full D-dimer Testing Market Report (Single-User License) Now: About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
